Improper anti-seizure medication (ASM) use and inappropriate brand-name-to-generic or generic-to-generic switching can lead to worsening clinical outcomes in epilepsy patients in the Gulf.

Both first-generation and newer ASMs can be considered and should be used appropriately from the beginning of treatment to ensure optimal clinical outcomes.

Inappropriate ASM switching should be avoided to prevent breakthrough seizures.

ASM switching (brand-name-to-generic, generic-to-generic, generic-to-brand name) can be considered for patients who are uncontrolled on current medication, but not for those who are in remission (controlled).